Aldeyra Therapeu ALDX

$0.63 +0.02 (2.89%)

Valuation

Market cap
37,155,000
Revenue TTM
$0
Net income TTM
$-33,850,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
547,100
Avg volume
1,260,138
Day's range
$0.58 – $0.70
Shares out
60,326,000
Stochastic %K
56%
Beta
1.32
Analysts
Moderate Buy
Price target
$6.25

Price

Company profile

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lympho...

Show more

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
781 761 4904
Website
https://www.aldeyra.com
Address
131 Hartwell Avenue, Suite 320, Lexington, United States

Latest news

Stocktwits

steven1x Nov 7, 4:01 AM
$ALDX https://ir.aldeyra.com/node/13276/html
0 replies
steven1x Nov 6, 2:40 PM
$ALDX Evening SEC recap — 6 new filings. **ALDX — 10-Q (Q3), filed Nov 5.** This confirms Q3 — the TickerOn "reported Nov 3" claim is now superseded by the actual filing. - Pre-revenue; net loss **$3.8m vs $5.5m in Q2**; cash **$41.0m vs $45.1m**; **no debt**. - **New: the reproxalap FDRR was submitted to FDA's Office of New Drugs on Oct 26**, appealing the March 16 CRL — first mention in a filing; OND meeting expected Q4 2026. Runway into **2029** per the 10-Q (not H2 2028 as the TickerOn piece claimed). AbbVie has not exercised its reproxalap option.
0 replies
d_risk Nov 6, 4:19 AM
$ALDX - Aldeyra Therapeutics Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +241.7% above peer average (40,798 vs 11,941 across 655 peers). Aldeyra said it submitted a formal request asking the FDA to reconsider its 2026 complete response letter for reproxalap. The company warned that the review could take time and may not lead to approval. #Biotechnology #RegulatoryRisk #DrugApproval #FinancialRisk #LitigationRisk 🟢 Added 🟠 Removed https://d-risk.ai/ALDX/10-Q/2026-11-05
0 replies
TheRagnirLothbrok Nov 5, 1:42 PM
Ticker SCAG had huge news, could go parabolic: Scage Future Enters into Strategic Cooperation Agreement with China Huaye Group SCAG has only 1.3 million shares float - Chinese - Watch it 👀🚀 $ALDX $NWBO $MMTLP $WXM ::
0 replies
TheRagnirLothbrok Nov 5, 1:38 PM
Ticker SCAG had huge news, could go parabolic: Scage Future Enters into Strategic Cooperation Agreement with China Huaye Group SCAG has only 1.3 million shares float - Chinese - Watch it 👀🚀 $ALDX $CYN $RDW $BULL added
0 replies
TheRagnirLothbrok Nov 4, 9:51 PM
Ticker SCAG had huge news today: Scage Future Enters into Strategic Cooperation Agreement with China Huaye Group SCAG has only 1.3 million shares float - Chinese - Watch it 👀🚀 $ALDX swing it
0 replies
Tonyboner Nov 4, 4:33 PM
$ALDX You can not compair this to OTLK tottaly diffrent drug and ball game.
0 replies
Tonyboner Nov 4, 4:32 PM
$ALDX Gap and trap, I would not go near this till fda say OK and accept the paperwork, it will be a 5c stock otherwise, will be worth a play with the FDA give the nod.
0 replies